Giselle C. Meléndez

TL;DR: Evidence indicating that estrogens administered in the perimenopausal transition or early in menopause are not harmful to the cardiovascular system and, when given for a few years for the treatment of menopausal symptoms, may slow the progression of atherosclerosis and reduce the postmenopausal cardiovascular disease burden seems convincing.

TL;DR: Three years after anthracycline-based chemotherapy, elevations in myocardial T1 and ECV occur independent of underlying cancer or cardiovascular comorbidities, suggesting that imaging biomarkers of interstitial fibrosis in cancer survivors are related to prior receipt of a potentially cardiotoxic cancer treatment regimen.

TL;DR: Early after Anth-bC, LV mass reductions associate with worsening HF symptomatology independent of LVEF, suggesting an alternative mechanism whereby anthracyclines may contribute to HF symptom atology and raising the possibility that surveillance strategies during Anth- bC should also assess LV mass.

TL;DR: These cine derived measures of circumferential strain correlate with early subclinical declines in LVEF, and can be obtained in 6¾ minutes from cine bSSFP LV short-axis images in 98.6% of patients receiving treatment for cancer with potentially cardio-toxic chemotherapy.

TL;DR: It is demonstrated that cardiac fibrosis induced by Anth-bC can be reduced by NK-1R blockade, and the residual fibrotic response is likely due to direct Dox effects on cardiac fibroblasts to produce collagen.